Biocryst director granted RSUs and stock options

BioCryst Pharmaceuticals director Amy E. McKee received equity compensation awards.

Rhea-AI Filing Summary

BioCryst Pharmaceuticals director Amy E. McKee received equity compensation awards. On the grant date, she acquired 15,294 shares of common stock through a restricted stock unit grant under the company’s Non-Employee Director Compensation Policy. Following this grant, she directly holds 47,177 common shares.

She was also granted an automatic stock option covering 33,540 shares of common stock at an exercise price of $8.50 per share, exercisable until June 11, 2036. The restricted stock units will vest on the first anniversary of the grant date, aligning her compensation with long-term shareholder interests.

Insider Trade Summary

Grant/Award: 48,834 shares

Grant/Award 2 txns

Insider McKee Amy E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	$0.00
Grant/Award	Common Stock	15,294	$0.00	$0.00

Holdings After Transaction: Automatic Stock Option Grant — 33,540 contracts (Direct); Common Stock — 47,177 shares (Direct)

Footnotes (2)

1. F1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
2. F2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

Restricted stock units granted: 15,294 shares Common shares held after grant: 47,177 shares Stock options granted: 33,540 options +2 more

5 metrics

Restricted stock units granted 15,294 shares Automatic non-employee director RSU grant on June 11, 2026

Common shares held after grant 47,177 shares Direct ownership of BioCryst common stock after RSU award

Stock options granted 33,540 options Automatic non-employee director option grant on June 11, 2026

Option exercise price $8.50 per share Exercise price for 33,540 stock options granted to Amy McKee

Option expiration date June 11, 2036 Expiration for Amy McKee’s automatic non-employee director options

Key Terms

Restricted Stock Units, Automatic Stock Option Grant, Director Compensation Policy

3 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Automatic Stock Option Grant financial

"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."

Director Compensation Policy financial

"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy")"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCryst (BCRX) director Amy McKee report in this Form 4 filing?

Amy McKee reported receiving equity compensation as a non-employee director, including restricted stock units and stock options. The filing shows automatic grants under BioCryst’s Non-Employee Director Compensation Policy, rather than open-market share purchases or sales, highlighting a routine element of director compensation structure.

How many BioCryst (BCRX) shares did Amy McKee receive as restricted stock units?

Amy McKee received 15,294 shares of BioCryst common stock through a restricted stock unit grant. These units were awarded at no cash cost to her and are scheduled to vest on the first anniversary of the June 11, 2026 grant date, subject to the policy’s terms.

What stock options were granted to Amy McKee by BioCryst (BCRX)?

Amy McKee was granted options to acquire 33,540 shares of BioCryst common stock at an exercise price of $8.50 per share. These automatic non-employee director options were granted under the Director Compensation Policy and are scheduled to expire on June 11, 2036, if not exercised earlier.

When do Amy McKee’s BioCryst (BCRX) restricted stock units vest?

The restricted stock units granted to Amy McKee will vest on the first anniversary of the grant date. The Form 4 states the grant occurred on June 11, 2026, so vesting is scheduled for the corresponding date in the following year, assuming continued eligibility under the policy.

How many BioCryst (BCRX) shares does Amy McKee own after these grants?

After the restricted stock unit grant, Amy McKee directly holds 47,177 shares of BioCryst common stock. This figure represents her reported direct ownership of common shares following the June 11, 2026 equity award and does not include shares underlying unexercised stock options.

Are Amy McKee’s BioCryst (BCRX) equity awards open-market transactions?

No, Amy McKee’s reported transactions are compensation-related grants, not open-market trades. The Form 4 classifies them as automatic non-employee director grants of restricted stock units and stock options under BioCryst’s Director Compensation Policy, with no purchase or sale of shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKee Amy E

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	47,177	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(2)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)